ENTITY
Zai Lab Ltd

Zai Lab Ltd (ZLAB US)

141
Analysis
Health Care • China
Zai Lab Limited operates as a bio-pharmaceutical company. The Company researches and develops therapeutic technology for antibody-based oncology, autoimmune, and infectious diseases treatments. Zai Lab also manufactures drugs in the form of capsules, injections, and liquids. Zai Lab serves patients worldwide.
more
•26 Jan 2020 11:42

ECM Weekly (26 Jan 2020) - Central Retail Corp, Smoore, Mindspace Biz Parks REIT, Elite Comm REIT

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Happy...

Share
bullish•Zai Lab Ltd
•22 Jan 2020 14:32

Zai Lab Placement: Positive Development Bodes Well for the Deal

Zai Lab announced a USD 300 million placement after market close. This is the third deal since its IPO in 2017. In this insight, we will discuss...

Logo
637 Views
Share
bullish•Zai Lab Ltd
•22 Jan 2020 12:00

Zai Lab Offering: Remains an Attractive Opportunity

Zai Lab Ltd (ZLAB US) unveiled plans to raise around $313 million (based on the closing price of $52.14 per ADS) through a primary offering of 5.5...

Logo
530 Views
Share
bullish•Zai Lab Ltd
•02 May 2019 22:19

Zai Lab Offering: Attractive Due to Strong Track Record

Zai Lab Ltd (ZLAB US) unveiled plans to raise around $125 million (based on the closing price of $26.65 per ADS) through a public offering of 5.0...

Logo
615 Views
Share
bearish•Zai Lab Ltd
•02 May 2019 15:36

Zai Lab Placement: Beware of Performance of Last Deal Despite Decent Fundamentals

Zai Lab announced an offering of 50 million ADS to raise up to USD 150 million. We have covered the company's IPO in 2017. In this insight, we will...

Logo
659 Views
Share
x